Cubist Pharmaceuticals Inc (NASDAQ:CBST) fell more than 5 percent in the current trading session after JMP Securities lowered its ratings for the biopharmaceutical company from �Outperform� to �Market Perform� in a research report released on 23rd of July.
Healthcare stocks advanced broadly on Wall Street on Wednesday morning, with the sector seeing an overall increase of 0.6%. More broadly, the Dow Jones Industrial Average remained flat, the Nasdaq increased 0.3% and the S&P 500 was unchanged.
You are also cautioned that any forward-looking statements reflect management's current views only and that the Company undertakes no obligation to revise or update such statements in the future. For simplicity sake and to focus on what we believe are ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) moved a step closer towards achieving its objective of having four antibiotics in the market by 2015 when the FDA approved Sivextro (200 mg: once daily for six days).